Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH director exits

This article was originally published in The Gray Sheet

Executive Summary

Elias Zerhouni will step down as director of the National Institutes of Health at the end of October, citing plans for "new opportunities, including several writing projects." Zerhouni, who was appointed to lead the 27-institute agency in 2002, is perhaps best known for two initiatives: the so-called NIH Roadmap, launched in 2003 to accelerate broad-reaching research projects that did not fit within the constructs of any single institute, and sweeping ethics reforms in 2005 that restricted NIH staffers from consulting with device and drug firms outside of formal government collaboration agreements. A trained radiologist, Zerhouni also used his stint at NIH to spotlight the benefits of medical imaging (1"The Gray Sheet" Feb. 6, 2006, p. 6)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026623

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel